Enter age + axial length. In 30 seconds you have a risk score, a growth chart, and a parent-ready report — while the patient is still in the chair.
Free account includes 3 saved first visits and 3 parent reports. Pro unlocks follow-ups, treatment comparison, Clinical Summary, QR sharing, and unlimited tracking · view limited sample preview
Designed around chairside workflow. No training required.
Designed to support chairside decision-making without replacing clinical judgment. Outputs are clearly labelled as educational decision support.
All projection values and treatment efficacy figures use documented model inputs. View clinical model transparency.
Every number has a source. The projection engine uses peer-reviewed normative datasets and RCT-derived efficacy values.
Composite risk score uses AL percentile (30%), growth velocity (28%), projected AL@18 (22%), parental myopia (12%), and near-work hours (8%). Weights derived from Tideman et al. 2018. The composite score is a clinical communication aid, not a validated diagnostic instrument.
Confidence intervals of ±5–10% apply. Individual outcomes vary. Population-average rates are applied; this tool does not account for individual biological variation.
Efficacy values represent change in axial elongation vs untreated control at ~2-year RCT endpoints — not final AL or cure rates. Treatment availability and regulatory approval vary by country; this site does not provide prescribing instructions. † Combination Therapy is a modeled composite (multiplicative formula, capped at 75% in-app); no single RCT validates this figure directly. Individual treatment defaults are conservative app coefficients for educational projections, not head-to-head clinical equivalence claims. See Methodology for the full model.
Public pages are educational previews. A free account saves 3 first visits and 3 parent reports. Pro unlocks follow-ups, treatment comparison, Clinical Summary, QR sharing, and unlimited tracking.
Detailed clinical guidance on myopia management topics — each page cites primary literature and links directly to the tool.
No. MyopiaTracker is a clinical decision support tool for visualization and patient education. It does not diagnose, prescribe, or replace clinical judgment. Not FDA-cleared as a medical device.
Projections use published normative sources including Tideman 2018, McCullough 2020, Chen 2025, and app-documented treatment coefficients. Confidence intervals of ±5–10% apply. Population-average rates; individual outcomes vary. See the clinical model.
Yes for the clinical workflow. Public pages are educational previews. A free clinician account saves 3 first visits and 3 parent reports; treatment comparison, Clinical Summary, QR sharing, and follow-up tracking require Pro.
Public preview data stays in the browser. Free accounts create a server-side login and limited cloud records for 3 first visits and 3 parent reports. A HIPAA Business Associate Agreement is available on Enterprise plans only.
Eight treatment options plus lifestyle reference: MiSight® 1 day, Stellest® (HALT), Ortho-K, MiyoSmart® (DIMS), Atropine 0.01%, 0.025%, 0.05%, Combination Therapy, and Outdoor/Behavioural context. Efficacy inputs are conservative defaults derived from published evidence.
Yes. The app is fully responsive and works on iPad and Android tablets. Clinical workflow features require a clinician account and active Pro trial or subscription.
Create a free account for 3 saved first visits and 3 parent reports. Start Pro when you need follow-ups and advanced tools.